Clinical and Immunologic Evaluation of Dendritic Cell–Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma

Jemal, 2007, Cancer statistics, 2007, Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43

Sener, 1999, Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the national cancer database, J Am Coll Surg, 189, 1, 10.1016/S1072-7515(99)00075-7

Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med, 350, 1200, 10.1056/NEJMoa032295

Burris, 1997, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, 2403, 10.1200/JCO.1997.15.6.2403

Okusaka, 2008, A late phase II study of S-1 for metastatic pancreatic cancer, Cancer Chemother Pharmacol, 61, 615, 10.1007/s00280-007-0514-8

Nakai, 2010, Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan, Jpn J Clin Oncol, 40, 774, 10.1093/jjco/hyq059

Sugiyama, 2005, Cancer immunotherapy targeting Wilms’ tumor gene wt1 product, Expert Rev Vaccines, 4, 503, 10.1586/14760584.4.4.503

Mukherjee, 2000, Mice with spontaneous pancreatic cancer naturally develop MUC-1–specific CTLs that eradicate tumors when adoptively transferred, J Immunol, 165, 3451, 10.4049/jimmunol.165.6.3451

Nair, 1999, Induction of carcinoembryonic antigen (CEA)–specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA, Int J Cancer, 82, 121, 10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X

Larbouret, 2007, In vivo therapeutic synergism of anti–epidermal growth factor receptor and anti-Her2 monoclonal antibodies against pancreatic carcinomas, Clin Cancer Res, 1, 3356, 10.1158/1078-0432.CCR-06-2302

Gjertsen, 1995, Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation, Lancet, 346, 1399, 10.1016/S0140-6736(95)92408-6

Hoffmann, 2000, Generation of T cells specific for the wild-type sequence p53 (264–272) peptide in cancer patients: implications for immunoselection of epitope loss variants, J Immunol, 165, 5938, 10.4049/jimmunol.165.10.5938

Inaba, 1994, The tissue distribution of the b7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro, J Exp Med, 180, 1849, 10.1084/jem.180.5.1849

Mayordomo, 1995, Bone marrow–derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity., Nat Med, 1, 1297, 10.1038/nm1295-1297

Thurner, 1999, Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma, J Exp Med, 190, 1669, 10.1084/jem.190.11.1669

Cheever, 2009, The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research, Clin Cancer Res, 15, 5323, 10.1158/1078-0432.CCR-09-0737

Oka, 2004, Induction of wt1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by wt1 peptide vaccine and the resultant cancer regression, Proc Natl Acad Sci U S A, 101, 13885, 10.1073/pnas.0405884101

Oka, 2006, Development of wt1 peptide cancer vaccine against hematopoietic malignancies and solid cancers, Curr Med Chem, 13, 2345, 10.2174/092986706777935104

Ramanathan, 2005, Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer, Cancer Immunol Immunother, 54, 254, 10.1007/s00262-004-0581-1

Plate, 2005, Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas, Cancer Immunol Immunother, 54, 915, 10.1007/s00262-004-0638-1

Soeda, 2009, Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer, Jpn J Clin Oncol, 39, 797, 10.1093/jjco/hyp112

Okamoto, 1998, cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro, Cancer Immunol Immunother, 47, 233, 10.1007/s002620050526

Okamoto, 2000, Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients, Anticancer Drugs, 11, 165, 10.1097/00001813-200003000-00004

Böyum, 1967, Isolation of mononuclear cells and granulocytes from human blood, Scand J Clin Invest, 21, 77

Okamoto, 2004, Expression of Toll-like receptor 4 on dendritic cells is significant for anti-cancer effect of dendritic cell–based immunotherapy in combination with an active component of OK-432, a streptococcal preparation, Cancer Res, 64, 5461, 10.1158/0008-5472.CAN-03-4005

Okamoto, 2003, Involvement of Toll-like receptor 4 signaling in interferon-γ production and anti-tumor effect by a streptococcal agent OK-432, J Natl Cancer Inst, 95, 316, 10.1093/jnci/95.4.316

Ahmed, 2004, Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of Toll-like receptor 4, J Immunother, 27, 432, 10.1097/00002371-200411000-00003

Okamoto, 2006, Mechanism of anti-cancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling, J Immunother, 29, 78, 10.1097/01.cji.0000192106.32206.30

Oshikawa, 2006, Anti-tumor effect of OK-432–derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent, J Immunother, 29, 143, 10.1097/01.cji.0000189028.18288.6f

Nakahara, 2003, Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide, Cancer Res, 63, 4112

Itoh, 2003, Streptococcal preparation OK432 promotes functional maturation of human monocyte–derived dendritic cells, Cancer Immunol Immunother, 52, 207, 10.1007/s00262-002-0337-8

Sato, 2003, Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2), Cancer Sci, 94, 1091, 10.1111/j.1349-7006.2003.tb01405.x

Kontani, 2002, Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model, Cancer Gene Ther, 9, 330, 10.1038/sj.cgt.7700444

Cannon, 2004, Immunological treatment of ovarian cancer, Curr Opin Obstet Gynecol, 16, 87, 10.1097/00001703-200402000-00015

Nagayama, 2003, Results of a phase I clinical study using autologous tumour lysate–pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2, Melanoma Res, 13, 521, 10.1097/00008390-200310000-00011

Chong, 1994, ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2–activated T cells, Cancer Immunol Immunother, 39, 127, 10.1007/BF01525318

Okamoto, 2001, Enhancement of anti-cancer immunity by lipoteichoic acid–related molecule isolated from a penicillin-killed group A Streptococcus, Cancer Immunol Immunother, 50, 408, 10.1007/s002620100207

Gorelik, 1994, Low-dose melpharan-induced shift in the production of a TH2-type cytokine to a TH1-type cytokine in mine bearing a large MOPC-315 tumor, Cancer Immunol Immunother, 39, 117, 10.1007/BF01525317

Takeuchi, 1997, TH2-like response and antitumor effect of anti–interleukin-4 mAb in mice bearing renal cell carcinoma, Cancer Immunol Immunother, 43, 375, 10.1007/s002620050347

Sakaguchi, 2004, Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses, Annu Rev Immunol, 22, 531, 10.1146/annurev.immunol.21.120601.141122

Wang, 2006, Regulatory T cells and Toll-like receptors in cancer therapy, Cancer Res, 66, 4987, 10.1158/0008-5472.CAN-05-4676

Li, 2010, Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the “2010 ASCO Annual Meeting.” Chicago, IL, USA. June 4–8, 2010, JOP, 11, 310

Miyazawa, 2010, Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer, Cancer Sci, 101, 433, 10.1111/j.1349-7006.2009.01416.x

Yanagimoto, 2007, Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer, Cancer Sci, 98, 605, 10.1111/j.1349-7006.2007.00429.x

Melief, 2008, Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines, Nat Rev Cancer, 8, 351, 10.1038/nrc2373

Bauer, 2007, Dendritic cell–based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model, Gut, 56, 1275, 10.1136/gut.2006.108621

Hirooka, 2009, A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer, Pancreas, 38, e69, 10.1097/MPA.0b013e318197a9e3

Keilholz, 2002, Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy, J Immunother, 25, 97, 10.1097/00002371-200203000-00001

Suzuki, 2007, Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects, Cancer Biol Ther, 6, 880, 10.4161/cbt.6.6.4090

Suzuki, 2005, Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity, Clin Cancer Res, 11, 6713, 10.1158/1078-0432.CCR-05-0883

Yano, 2006, A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro, Oncol Rep, 16, 147

Valteau-Couanet, 2002, Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients, Blood, 100, 2554, 10.1182/blood.V100.7.2554